Abbotsford British Columbia

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Prostate cancer3 trials
• Bladder cancer2 trials
• Metastatic breast cancer2 trials
• Coronary artery disease1 trial
• Gastric and oesophageal cancer1 trial
• Heart failure1 trial
• Lung cancer1 trial
• Ovarian cancer1 trial

Phase

• Phase 312 trials

Status

• Active, not recruiting3 trials
• Not yet recruiting3 trials
• Recruiting3 trials
• Withdrawn2 trials
• Completed1 trial

Lead sponsor

• AstraZeneca11 trials
• DalCor Pharmaceuticals1 trial

Running trials

• Recruiting

  Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

  NCT07816666· Phase 3· AstraZeneca· Source

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· AstraZeneca· Source

• Recruiting

  An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  NCT07720284· Phase 3· AstraZeneca· Source

• Recruiting

  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  NCT07431281· Phase 3· AstraZeneca· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· Phase 3· AstraZeneca· Source

• Recruiting

  Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

  NCT05918861· Phase 3· DalCor Pharmaceuticals· Source

  Contact: David Kallend, MBBS

• Active, not recruiting

  Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

  NCT04960709· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

  NCT04862663· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer1 recruiting
• Coronary artery disease1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Heart failure1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· AstraZeneca· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  NCT06627647· Phase 3· AstraZeneca· Source

• Completed

  A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

  NCT01602380· Phase 3· AstraZeneca· Source